Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensiv... ( Single Molecule with Dual Mechanis...)

HOME >> MEDICINE >> TECHNOLOGY

Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients

Date:5/16/2008

Single Molecule with Dual Mechanism May Offer Novel Approach to Blood

Pressure Management

NEW ORLEANS, May 16 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today that PS433540, its first-in-class Dual Acting Receptor Antagonist (DARA), showed statistically significant blood pressure reductions in a Phase 2a study in patients with mild to moderate hypertension. PS433540 is being developed as a potential treatment for both hypertension and diabetic nephropathy and is a novel blood pressure product candidate that possesses two validated mechanisms of action in a single molecule. The data will be presented today at the Recent and Late Breaking Clinical Trials Session at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition in New Orleans.

The Phase 2a study met its primary endpoint by showing a statistically significant reduction in mean 24-hour systolic ambulatory blood pressure over placebo. The study also showed statistically significant improvements over placebo in mean 24-hour diastolic ambulatory blood pressure as well as seated blood pressure. In this double-blind, placebo-controlled study, patients treated with 200 mg of PS433540 once daily experienced a 12/9mmHg drop in mean 24-hour systolic and diastolic blood pressure and those treated with 500 mg experienced a 15/10mmHg drop in mean 24-hour systolic and diastolic blood pressure. These reductions were highly statistically significant vs. placebo (P<0.001). Mean seated office systolic and diastolic blood pressure, the typical blood pressure measure, was also evaluated, with observed blood pressure drops of 17/11mmHg with the 200 mg dose and 17/10mmHg with the 500 mg dose (P<0.001 vs. placebo).

Once-daily treatment with 200 or 500 mg of PS433540 was well tolerated. Most of the adverse events reported were mild o
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis

Post Your Comments:

(Date:5/24/2013)... 2013 In accordance with Rule 17.1 and Rule ... the United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty ... Corporation (NYSE: ELN). Background On 2 ... offer for the entire of the issued and to be ... Offer"). On 20 May 2013, Royalty Pharma ...

(Date:5/23/2013)... WASHINGTON , May 23, 2013 Vanda Pharmaceuticals Inc. ... company has been named the 2013 Life Science Firm of ... (TCM). Vanda was honored at the TCM,s 25 ... Bethesda , Maryland. The Tech Awards Celebration recognizes the ... in Maryland and the surrounding regions. ...

(Date:5/23/2013)... 2013 Nephros, Inc. (OTC Bulletin Board: ... that develops and sells high performance liquid purification ultrafilters, ... In addition, the concurrent temporary reduction in exercise price ... 17, 2013. Nephros estimates that it will ... offering. A portion of the proceeds will be used ...

Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9 Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2 Nephros Announces Completion of Rights Offering 2 Nephros Announces Completion of Rights Offering 3 Nephros Announces Completion of Rights Offering 4

[0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland [0] Nephros Announces Completion of Rights Offering

... Pharmaceuticals, Inc. (NASDAQ: OPTR ) announced today ... antibiotics in two Phase 3 clinical trials exploring the ... adult patients with Clostridium difficile -associated diarrhea (CDAD) ... Clinical Infectious Diseases (CID). The analysis found ...

... 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... CMED ), a leading China-based advanced ... unaudited financial results for the first ... ("1Q FY2011") today.1 Q FY20 ...

Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin China Medical Technologies Reports First Fiscal Quarter Financial Results

(Date:5/24/2013)... KC and Monica Craichy, Founders of ... Their oldest sons, Kyle and Austin Craichy, will be kiteboarding ... several professional kiteboarders. , KC Craichy said he is excited ... come together such that virtually everyone who planned to be ... kite boarders will meet at Matheson Hammock Park and Beach ...

(Date:5/24/2013)... Mirena IUD lawyers at the Rottenstein Law Group ... more than 59,229 complaints since 2004 from women claiming they ... known as the Mirena IUD.* , Among the most common ... ‘expulsion,’ where the IUD came out on its own. There ... News article. “Abdominal pain is also common, with 3,774 complaints. ...

(Date:5/24/2013)... Denver, CO (PRWEB) May 24, 2013 ... SEO analysis, in partnership with JD Media Surge, a ... , The dental SEO analysis service will focus ... high in the search engines for their competitive keywords. ... the dentists website and recommendations based on what their ...

(Date:5/24/2013)... 24, 2013 Gift Card Network ... competitors in sustainable card material, are combining forces ... materials as a sustainable gift card substrate. , ... industry challenges and increase education and usage of ... support the reduction of carbon footprint and environmental ...

(Date:5/24/2013)... 24, 2013 Started in 1982, AMTC’s SHINE ... Orlando. 2013 marks AMTC’s 31st anniversary. SHINE is a ministry ... supermodel Millie Lewis and her daughter, Carey Lewis Arban. , ... casting directors, and music professionals including the New York Film ... Media. They are kings of Hollywood and Christian casting directors. ...

Breaking Medicine News(10 mins):Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2 Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3 Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2 Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3 Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2

[0] FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa [0] Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes [0] Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge [0] Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants [0] AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013

... studies that was presented yesterday at Digestive Disease Week? ... compounds can sustain relief for these patients with symptoms ... to review the therapeutic benefits for irritable bowel syndrome ... of the bowel disorders like IBS and Crohn's disease ...

... surgeon Dr Jerome Blanchard who had removed the wrong kidney ... , ,The disciplinary hearing was told yesterday that ... a patient and left her dependent on dialysis, as he ... Blanchard took out his patient’s transplant kidney, which was still ...

... says that each time an elderly person falls at ... two days of crew time.// ,Significant numbers ... suggesting that these facilities are relying on ambulance services ... calls for falls made to the ambulance service in ...

... on 100 soft drinks and beverages by the FDA (Food ... the presence of benzene//, a carcinogen in much higher amount ... ,FDA had alerted these companies, and they had ... done so. Though environmental companies had expressed concern regarding this, ...

... facility for the Medical Linear Accelerator (LINAC) here under ... (DIT). ,The Society for Applied Microwave Electronics ... which pioneered the development of an indigenous Medical LINAC, ... a cost of Rs 24.88 crore, DIT Secretary D ...

... such as gastric bypass and laparoscopic reflux ... reflux// disease respectively, are becoming popular, highlights ... Week, which represents the largest gathering of ... such as gastroenterology, endoscopy, gastrointestinal surgery and ...

Cached Medicine News:Health News:New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders 2 Health News:New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders 3 Health News:Consultant Bungles A Kidney Surgery 2 Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 2 Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 3 Health News:Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity 2 Health News:Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity 3

New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders Consultant Bungles A Kidney Surgery Ambulance Services Cost ?145 Each Time An Elderly Person Sustains A fal Soda Drinks Contain Benzene - A Carcinogen, Reports FDA Medical LINAC Machine Manufacturing Unit At Khargar Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

Medicine Products:

Vitamin E, Serum or Plasma Vitamin D, 25-Hydroxy Vitamin B12 & Folate Vitamin B6 (Pyridoxine), Total, Plasma